4Q24 & 2024
EARNINGS
CONFERENCE CALL
2024 Overview
Jonas Marques, CEO
Beginning of
a New Cycle
In 2024, we established the foundation for the company's next growth phase.
1
DIAGNOSIS
- Active listening
- Top leadership workshop
- Patterns and correlations
2
MANAGEMENT
MODEL
- Formation of the executive team
- Changing attitudes and behaviors
- Operational Missions
3
STRATEGY
ACCELERATION
- Communication and engagement
- Central focus on operations
- Execution of large campaigns (Black Friday)
4
Formation of an
Impact Team
5
Simple people, on extraordinary missions
THOUSANDS
of impacted employees
MILLIONS
of satisfied customers
HUNDREDS
of stores visited
6
We continue to make progress on our
strategic pillars,
building a foundation for long-term growth
21 million | engagement from |
Increased | |
active customers | continuous |
care | |
customers |
16,6% of | 9,9% of |
omnichannel | omnichannel |
sales | customers |
Maturation of the first post- IPO store cohort,
delivering projected sales and IRR targets
6.2 million
Clinic Farma consultations
7
Numbers follow behaviors
Fourth quarter of sales acceleration, ensuring margin expansion and record market share
GROSS REVENUE
R$3.6 billion (+17.4% vs 4Q23)
with 17.1% same store sales
GROSS PROFIT
R$1.1 billion (+19.5% vs 4Q23)
gross margin of 29.7% (+0.5p.p. vs 4Q23)
ADJ. EBITDA
R$ 164.0 million (+31.6% vs 4Q23)
EBITDA margin of 4.6% (+0.5p.p. vs 4Q23)
MARKET SHARE
6.5% of national market share
+35bps vs 4Q23 with gains in all regions
EXTRAFARMA SYNERGIES
Top of guidance exceeded
R$ 267 million on an annualized basis
ADJ. NET INCOME
R$ 77.1 million (+22.8% vs 4Q23)
R$ 152 million in 2024 (vs R$ 14.2M in 2023)
8
4Q24 & 2024 Results
Luiz Novais, CFO
Sales Performance
Fourth quarter of acceleration, optimal combination of robust growth in customer traffic and average ticket above inflation
TOTAL GROWTH¹
(% annual change)
New Stores Same Stores Closed Stores
GROWTH BREAKDOWN
(% annual change)
Average Ticket
# of Tickets
6.4% |
6.9%
5.9%
7.6%
17.4%
1.4%
6.9% | 3.4% |
0.7% | |
4.9%
7.6%
9.1%
7.7%
2.9%
5.5%
(0.7%)
4Q23
10.0%
1.5%
9.5%
(1.0%)
1Q24
12.2%
1.7%
11.3%
(0.9%)
2Q24
13.9%
1.3%
13.5%
(0.9%)
3Q24
17.0%
(1.0%)
4Q24
4Q23 1Q24 2Q24 3Q24 4Q24
MATURE STORES REAL GROWTH
(% annual change)
MSSS | CMED | 16.4% | ||
15% | ||||
10% | 3.6x | |||
5% | 4.5% | |||
0% | ||||
4Q23 | 1Q24 | 2Q24 | 3Q24 | 4Q24 |
10
Banner Performance
Strong growth across both banners, with converted Extrafarma stores significantly outperforming the average
SAME STORE SALES
(% annual change)
29.5%
19.8%
17.1% 16.5%
14.8%
Total | Pague | Extrafarma | Extrafarma | Extrafarma |
Portfolio | Menos | (converted) | (not | |
converted) |
MONTHLY AVERAGE SALES PER STORE
(R$ thousand)
Pague Menos | Extrafarma | Gap Pague Menos x Extrafarma |
800 | |||||||||||
700 | |||||||||||
600 | |||||||||||
500 | |||||||||||
400 | 28% | 26% | 25% | 27% | 25% | 26% | |||||
22% | 20% | 19% | 20% | 18% | |||||||
300 | |||||||||||
200
2Q22 3Q22 4Q22 1Q23 2Q23 3Q23 4Q23 1Q24 2Q24 3Q24 4Q24
Note: Extrafarma Portfolio considers stores that have undergone banner conversion.
11
| Attention: This is an excerpt of the original content. To continue reading it, access the original document here. |